| Overview |
| bs-3331R-APC-Cy5 |
| PFK2 (Ser467) Polyclonal Antibody, APC-Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| This phosphorylated site is homologous to that of Ser467 in Mouse and Ser496 in Rat. |
| Human, Mouse, Rat |
| Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human PFK2 around the phosphorylation site of Ser467 |
| Ser467 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5209 |
| Q16875 |
| Cytoplasm, Nucleus |
| PFK2; IPFK2; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; 6PF-2-K/Fru-2,6-P2ase 3; PFK/FBPase 3; 6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme; Renal carcinoma antigen NY-REN-56; iPFK-2; PFKFB3 |
| 6 Phosphofructo 2 Kinase plays a role in the synthesis and degradation of fructose 2,6-bisphosphate. Fructose-2,6-bisphosphate acts as an allosteric regulator of 6-phosphofructo-1-kinase (PFK1), which catalyses a key step in the glycoytic pathway. Glycolytic flux is key to tumour growth, and small molecule inhibition of 6 Phosphofructo 2 Kinase suppresses both glycolytic flux and tumour growth. Several lines of evidence suggest that 6 Phosphofructo 2 Kinase is also involved in obesity. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz